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The early events in Crimean–Congo hemorrhagic fever virus (CCHFV) have not been completely characterized.
Earlier work indicated that CCHFV likely enters cells by clathrin-mediated endocytosis (CME). Here we provide
conﬁrmatory evidence for CME entry by showing that CCHFV infection is inhibited in cells treated with
Pitstop 2, a drug that speciﬁcally and reversibly interferes with the dynamics of clathrin-coated pits.
Additionally, we show that CCHFV infection is inhibited by siRNA depletion of the clathrin pit associated
protein AP-2. Following CME entry, we show that CCHFV has a pH-dependent entry step, with virus
inactivation occurring at pH 6.0 and below. To more precisely deﬁne the endosomal trafﬁcking of CCHFV,
we show for the ﬁrst time that overexpression of the dominant negative forms of Rab5 protein but not
Rab7 protein inhibits CCHFV infection. These results indicate that CCHFV likely enters cells through the
early endosomal compartment.
Published by Elsevier Inc.Introduction
The family Bunyaviridae consists of more than 350 virus
members divided among ﬁve genera (Hantavirus, Nairovirus,
Orthobunyavirus, Phlebovirus, and Tospovirus). Many bunyaviruses
are important human or plant pathogens. The nairovirus Crimean–
Congo hemorrhagic fever virus (CCHFV) is highly pathogenic for
humans, causing a disease characterized by the abrupt onset of
acute febrile illness that can progress to hemorrhage, multiple
organ failure, and shock. The case-fatality rate for CCHF ranges
from 3% to 70% (Ergonul, 2012; Sidira et al., 2011) [reviewed in
Schmaljohn and Nichol (2007)]. CCHFV is transmitted to humans
primarily by tick bite, but can also be contracted through direct
exposure to blood and tissues of infected humans or livestock.
CCHFV has the widest distribution of any tick-borne virus causing
human disease, and is found in over 30 countries throughout partsInc.
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hool of Veterinary Medicine,of Europe, the Middle East, Asia, and Africa (Leblebicioglu, 2010;
Vorou et al., 2007). Human-to-human transmission has made
nosocomial infections a public health concern; moreover, second-
ary cases are reported to be more severe and have higher lethality
than primary cases (Whitehouse, 2004).
Like all bunyaviruses, CCHFV has a host-derived lipid envelope
and a trisegmented, single-strand RNA genome. The large (L),
medium (M), and small (S) segments minimally encode the RNA-
dependent RNA polymerase, two transmembrane glycoproteins
(GN and GC), and the nucleocapsid protein (N), respectively, in the
virus complementary RNA [reviewed in (Schmaljohn and Nichol,
2007)]. Virions possess spike-like projections consisting of multi-
mers of GN and GC, which interact with host cell receptors to
initiate infection (Battisti et al., 2010; Overby et al., 2008; Sanchez
et al., 2002; Sherman et al., 2009) and which are the primary
targets for the host's neutralizing antibody response.
Following host receptor engagement, enveloped virions either
fuse directly with the plasma membrane, or are internalized and
subsequently fuse with endosomal membranes. Several endocytic
pathways have been implicated in the entry of enveloped virions,
such as clathrin-mediated endocytosis (CME), caveolar/raft-mediated
endocytosis, macropinocytosis, and other less characterized mechan-
isms that are clathrin- and caveolae-independent [reviewed in
Gruenberg (2009) and Schelhaas (2010)]. Early entry events for
bunyaviruses are not well understood, and the few published studies
Fig. 1. Disription of clathrin-coated vesicle dynamics with Pitstop 2 inhibits CCHFV
infection. A549 cells were treated at 37 1C with each concentration of Pitstop 2 or a
DMSO-matched control in triplicate, and infected as described in Materials and
Methods. The percentage of infected cells was determined by HCI and normalized
to the DMSO matched control. At least 6000 cells were scored per experimental
point. The data shown for VSV, CCHFV, and VACV represent two experiments, the
data shown for CCHFV and VSV were obtained in the same experiment. *p-values
for both CCHFV and VSV-GFP comparing 0 mM to 15 mM of Pitstop 2 (p¼0.0001).
Conﬁdence interval was set to 95%.
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family. For example, the hantavirus Hantaan virus (HTNV) (Jin et al.,
2002), and the orthobunyaviruses Oropouche virus (OROV) (Santos
et al., 2008) and La Crosse virus (LACV) (Hollidge et al., 2012) enter
cells by CME. In contrast, the phlebovirus Uukuniemi virus (UUKV)
enters DC-SIGN-negative cells (A549 cells) primarily via non-coated
vesicles, but enters DC-SIGN expressing cells mainly through a
clathrin-dependent mechanism (Lozach et al., 2011; Lozach et al.,
2010). Rift Valley fever virus (RVFV), another phlebovirus, is the only
bunyavirus reported thus far to enter cells via a caveolin-dependent
mechanism (Harmon et al., 2012).
CCHFV presents challenges for entry studies, in that the virus
requires BSL-4 containment, and grows to low titers in cell culture
(Bergeron et al., 2007). Because it is difﬁcult to achieve a sufﬁcient
multiplicity of infection (MOI) with CCHFV to perform confocal
microscopy studies to visualize co-localization of virus and cla-
thrin vesicle markers, or even to perform fusion bypass studies,
more indirect methods involving inhibition of infection must
be used. To date, only a single study of CCHFV entry has been
published in which two CME inhibitors, sucrose and chlorproma-
zine, were found to reduce infection by CCHFV as measured by
reduced expression of viral nucleocapsid protein in treated as
compared to untreated cells (Simon et al., 2009). Also in this study,
viral RNA synthesis and protein expression were both found to be
inhibited after treatment with clathrin-speciﬁc siRNAs. Although
these data support a CME-dependent entry mechanism for CCHFV,
neither of the approaches provide deﬁnitive proof for CME. For
the inhibitor approach, it has been shown that chlorpromazine
not only disrupts clathrin-coated pits, but also interferes with the
biogenesis of large intracellular vesicles including phagosomes
and macropinosomes (Elferink, 1979; Watanabe et al., 1988). The
use of hypertonic sucrose is also nonspeciﬁc in that it has been
shown to decrease both clathrin-coated pits and non-coated
invaginations in ﬁbroblasts, as well as to reduce macropinocytosis
and lipid-raft uptake (Bradley et al., 1993; Carpentier et al., 1989;
Synnes et al., 1999). Although siRNA treatment is more speciﬁc,
one of the negative-control siRNAs used in this study was found to
inhibit infection to the same extent as the clathrin heavy-chain-
speciﬁc siRNA in one of the cell types tested and there were no
clathrin-dependent or independent viruses included to provide
controls. Finally, because clathrin is important for cellular pro-
cesses other than CME, such as membrane trafﬁcking between the
trans-Golgi network (TGN) and endosomes, and formation of the
mitotic spindle, clathrin disruption alone cannot be relied upon as
conclusive evidence for CME-dependent virion entry [reviewed in
(Deborde et al., 2008; McMahon and Boucrot, 2011; Royle et al.,
2005)]. In the study reported here, we sought to substantiate the
role of CME in CCHFV entry by identifying an association of the
virus with another protein integral to CME that is not known to be
involved in other host cell processes.
Following internalization within host endocytic vesicles, envel-
oped virions typically require fusion between the virion and
host membranes to release their genomes into the cytosol. These
membrane fusion events can be either low pH-dependent or
-independent. For low pH-dependent viruses, the acidic environ-
ment in endosomal vesicles typically triggers conformational
change(s) in the viral glycoproteins leading to their insertion into
the host membrane, which promotes virus-host membrane mixing
and eventually leads to fusion. The moderately acidic environment
(pH≈6.2) within early endosomes (EE) is sufﬁcient to promote the
fusion conformation in the viral glycoproteins of some viruses,
while other viruses require the more acidic environment (pH≈5.5)
of the late endosome (LE) [reviewed in Gruenberg (2009)]. The
endosomal requirements of bunyaviruses have been studied by
colocalization with resident endosomal proteins, pH dependency
for infection, or over-expression of a dominant negative (DN) EERab GTPase (Rab5), which is required for EE maturation to LE. To
date, UUKV, HTNV, and OROV have been found to promote fusion
within LE (Jin et al., 2002; Lozach et al., 2010; Santos et al., 2008),
whereas evidence suggests that LACV and the RVFV fuse with EE
membranes (Filone et al., 2006; Hollidge et al., 2012; Pekosz and
Gonzalez-Scarano, 1996; Plassmeyer et al., 2005; Plassmeyer et al.,
2007). Fusion requirements for CCHFV have not yet been deﬁned.
In our studies, we identify pH requirements for CCHFV fusion as
well as the likely endosomal compartment in which fusion occurs.
This work extends the current knowledge of the requirements for
CCHFV infection by deﬁning two critical requirements for entry.Results and discussion
Pitstop 2 inhibits CCHFV infection
To analyze whether CCHFV uses CME for cellular entry, we
inhibited clathrin function using the small molecule inhibitor
Pitstop 2. Pitstop 2 has been shown to speciﬁcally and reversibly
disrupt the interaction of clathrin and endocytic accessory proteins
by binding to the terminal domain of the clathrin heavy chain,
thereby interfering with the dynamics of clathrin-coated pits
(von Kleist et al., 2011). To quantify viral infections, we developed
and optimized speciﬁc and reproducible automated high-content
image-based (HCI) assays in A549 and 293T cells for CCHFV
infections as well as the other viruses used as controls throughout
this study.
We found that Pitstop 2 treatment of target cells signiﬁcantly
decreased CCHFV infection (po0.0001) (Fig. 1), supporting CME
as a primary entry mechanism. Similarly, infection by the CME-
dependent control virus, vesicular stomatitis virus expressing
eGFP (VSV-GFP), was dramatically reduced in the presence of
Pitstop 2 (po0.0001) (Fig. 1), but the compound had little effect
on infection by the CME-independent control virus, vaccinia virus
expressing eGFP (VACV-GFP) (Fig. 1). We also measured the effect
of Pitstop 2 on infected cells to rule out cytotoxicity as the cause of
A.R. Garrison et al. / Virology 444 (2013) 45–54 47reduced viral replication. We found that Pitstop 2 did not appre-
ciably alter either the number of cells or the morphology of cells at
any of the concentrations used in this assay (data not shown).
These studies indicate that functional clathrin-coated pits are
required for CCHFV infection, suggesting that that CCHFV uses
CME for entry.
siRNA-mediated knockdown of AP2 inhibits CCHFV infection
In contrast to the initial description of Pitstop 2 (von Kleist
et al., 2011), a recent report suggests that Pitstop 2 can also inhibit
clathrin independent endocytosis of cargo proteins and that siRNA
knockdown of clathrin does not rescue inhibition of the endocy-
tosis of these proteins (Dutta et al., 2012). An earlier study in
which CME was implicated in CCHFV entry also included siRNA
knockdown of clathrin (Simon et al., 2009). To provide more
speciﬁc support for CME for CCHFV, we examined the dependence
of CCHFV infection upon the functionality of another protein
important to clathrin-coated pit formation, AP2. AP2, which is
the second most abundant protein after clathrin in clathrin-coated
pits, is not known to be involved in host cell processes other than
CME (Blondeau et al., 2004). AP2 is a heterotetramer of two large
adaptins (α-type subunit AP2A1 or AP2A2 and a β-type subunit
AP2B1), one medium adaptin (μ-type subunit AP2M1) and one
small adaptin (s-type adaptin AP2S1) (McMahon and Boucrot,Fig. 2. Depletion of AP2 inhibits CCHFV infection. (A and B) The AP2A1 and AP2A2 siRN
subunit of AP2. A549 cells were transfected with each siRNA in replicates of three and inf
siRNA were infected with CCHFV, VACV-GFP, or VSV-GFP. The percent of infected cells wa
represent three separate experiments, and the data shown for VACV-GFP and VSV-GFP re
knockdown mediated by the siRNAs at 48 h posttransfection. The negative control siRNA
calculated from the cycle threshold (Ct) using the ΔΔCt method, which corrects the differ
gene control. The data shown are from a single experiment. (C and D) The AP2M1 siR
replicates of three 48 h apart and infected with virus 48 h after the second transfection.
or EBOV-Z76 PsV. The percent of infected cells was normalized to the negative siRNA
treated cells by western blotting. Results are presented as percentages of AP2 levels in c
control siRNA and levels of GAPDH, which was used as a loading control. The western blo2011). To deplete AP2, we transfected A549 cells with siRNAs
directed against the two α isoforms (AP2A1 and AP2A2), and the μ
(APM1) subunits of AP2 and then infected the cells with CCHFV.
We conﬁrmed the activity of the siRNAs on all of the AP2 subunits
by measuring mRNA transcript levels of each by qRT-PCR (Fig. 2B).
Due to the abundance of AP2 in the cell, the moderate decreases in
AP2A1, APA2, and AP2M1 mRNA after siRNA treatment were not
surprising. Nevertheless, treatment of cells with these AP2-speciﬁc
siRNAs resulted in a statistically signiﬁcant reduction in CCHFV
infection (AP2A1 po0.01, AP2A2 po0.001, and AP2M1 po0.001)
(Fig. 2A) whereas the AP2-speciﬁc siRNAs had no effect on
infections with two AP2 independent control viruses, VACV-GFP
or VSV-GFP. VACV does not use CME and even though VSV does
enter by CME, it was found to not require the presence of AP2 in at
least one cell line, possibly because it is able to use another
adapter protein that has yet to be identiﬁed (Johannsdottir et al.,
2009).
To conﬁrm these ﬁndings and to provide stronger evidence of
AP2 knockdown at the protein level, we performed an additional
study in which we depleted AP2 with siRNA directed against the μ
(APM1) subunit using a previously described double knockdown
method (Bhattacharyya et al., 2011; Johannsdottir et al., 2009) and
then infected the cells with CCHFV. We conﬁrmed the activity of
the AP2M1 siRNA by measuring the AP2-α and AP2-μ protein
levels in treated cells by western blot analysis (Fig. 2D). Our resultsA target the two isoforms of the α subunit of AP2, the AP2M1 siRNA targets the μ
ected with virus 48 h later. (A) A549 cells transfected with AP2A1, AP2A2, or AP2M1
s normalized to the negative siRNA control (Cont siRNA). The data shown for CCHFV
present three replicates from a single experiment. (B) qRT-PCR results of the mRNA
samples (Cont siRNA) were set to 1 and the relative RNA levels of each siRNA were
ence between the negative siRNA control and the other siRNAs based on an internal
NA targets the m subunit of AP2. A549 cells were transfected twice with siRNA in
(C) A549 cells transfected with AP2M1 siRNA were infected with CCHFV, VACV-GFP,
control (Cont siRNA). (D) Quantitation of AP2-m and AP2-α protein levels in siRNA
ells treated with AP2M1 and normalized to control cells treated with the negative
t data are representative of two experiments. *Conﬁdence intervals were set to 95%.
Fig. 3. CCHFV cell entry is acid-dependent. 293T cells were pre-treated with NH4Cl
at various concentrations as shown for 60 min before infection, in replicates of six,
with VSV-GFP, CCHFV, or EBOV-GFP and incubated for 16, 24, and 48 h, respectively.
The cells were ﬁxed in 10% formalin, and CCHFV N and both eGFP viruses were
detected as described in Materials and Methods. The percent of infection was
determined in each experimental point utilizing HCI, and normalized to the mock-
treated control for each virus.
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knockdown of one subunit of AP2 results in the downregulation
of other subunits of the complex (Fig. 2D) (Johannsdottir et al.,
2009; Motley et al., 2003). Treatment of cells with AP2-speciﬁc
siRNA resulted in a statistically signiﬁcant reduction in CCHFV
infection (p¼0.0037) (Fig. 2C), whereas the AP2-speciﬁc siRNAs
had no effect on infections with the AP2 independent control virus
VACV-GFP (Johannsdottir et al., 2009). As an AP2 dependent
positive control for this experiment, we included Ebola Zaire'76
pseudovirions (EBOV-Z76 PsV) (Bhattacharyya et al., 2011). We
found that treatment with AP2M1-speciﬁc siRNA signiﬁcantly
reduced EBOV-Z76 PsV infection (p¼0.002). Together our data
not only provide additional evidence for the CME entry pathway
for CCHFV, but also suggest for the ﬁrst time that AP2 is likely to be
a cargo adapter for CCHFV internalization.
CCHFV infection is low pH-dependent
After internalization within clathrin-coated vesicles, cargo that
enters the degradative pathway is sorted into endosomes that
become increasingly acidic as they mature from EE to LE [reviewed
in McMahon and Boucrot (2011)]. The weak base NH4Cl is known
to concentrate in endocytic vesicles and neutralize their lumenal
pH (Galloway et al., 1983). Thus, NH4Cl is a useful tool to assess
whether virion-host membrane fusion is pH-dependent. In addi-
tion, the relative sensitivity of virion infection to NH4Cl can
provide clues as to whether the viral genome gains access to the
cellular cytoplasm by fusing with membranes of the EE or LE since
virions that require the lower pH environment of LE as compared
to EE are generally more sensitive to NH4Cl treatment. To this end,
we treated HEK 293T cells with various concentrations (1–25 mM)
of NH4Cl and then measured CCHFV replication. For comparison,
we measured the effect of NH4Cl treatment on infection by
VSV-GFP, which fuses in EE, or by a recombinant ebolavirus
expressing GFP (EBOV-GFP) which fuses in LE. We observed
variable cytotoxicity at the highest concentration of NH4Cl
(25 mM) for all viruses (EBOV—35%, VSV—16%, CCHFV—20%),
but there was no apparent cytotoxicity below 25 mM. Consistent
with their LE and EE trafﬁcking requirements, EBOV-GFP was
found to be more sensitive to NH4Cl treatment than VSV-GFP
(Fig. 3). CCHFV had an intermediate sensitivity, but appeared to be
more similar to VSV than to EBOV, particularly at NH4Cl concen-
trations below 6.25 mM. These data demonstrated that CCHFV has
a low pH requirement for infection. Although these pH studies are
consistent with CCHFV entry into the cytoplasm using endosomal
fusion, other interpretations are also possible, such as blocking the
import of necessary host factors. Consequently, additional experi-
ments were required to support this entry mechanism.
To more speciﬁcally characterize the pH threshold of fusion for
CCHFV, we performed a pH sensitivity assay in which we incu-
bated virus in buffers ranging from pH 5.0 to 7.0. These pH values
mimic conditions that would be encountered in the EE and the LE.
The pH that is critical for CCHFV fusion should promote conforma-
tional changes in the glycoprotein that is responsible for fusion
and render it unable to infect host cells. As control viruses, we
similarly treated VSV-GFP and Nipah pseudovirions (NiV-PsV),
which are pH-dependent and -independent viruses respectively,
and then assessed their infectivity. We found that CCHFV infectiv-
ity declined after treatment at pH 6.0 or 5.5, but not at pH 6.5 or
7.0 (Fig. 4A, B). Consistent with earlier studies showing that the
pH threshold for conformational changes in the VSV G protein
required for fusion with endosomal membranes is 6.2 (Carneiro
et al., 2001; White et al., 1981), we observed a substantial decline
in VSV infectivity at pH 6.0 and complete inhibition of infectivity at
pH 5.5 (Fig. 4A). In contrast, NiV-PsV remained infectious even at
pH 5.0 (Fig. 4A).These data demonstrated that a mildly acidic environment
characteristic of the EE appears to be sufﬁcient to block CCHFV
infectivity, presumably by triggering a conformational change in
the CCHFV fusion protein.
CCHFV enters cells via the EE
To conﬁrm that CCHFV gains access to the cytoplasm by fusing
in the EE, we performed studies using dominant negative EE- or
LE-speciﬁc Rab proteins. Rab5 (EE) and Rab7 (LE) associate with the
membranes of their respective vesicles and shuttle cargo through
interactions with effector proteins [reviewed in Schelhaas (2010)]
(Stenmark et al., 1994a, 1994b). Rab5 and Rab7 dominant negative
(DN) proteins harbor single amino acid changes that prevent the
exchange of GTP for GDP on the protein, thus maintaining the
proteins in an inactive state so they can no longer bind to their
effectors. When these mutant proteins are overexpressed in cells,
they elicit a dominant negative effect over the wild-type protein,
thus rendering the endogenous protein ineffective. A virus that
requires either the EE or the LE for trafﬁcking will be adversely
affected by the DN Rab protein associated with each endosomal
compartment.
To examine the role of EE in CCHFV entry, we transfected HEK
293T cells with plasmids expressing either control pEGFP-C1, wild-
type (WT) Rab5 or the DN mutant Rab5 S34N fused to eGFP, and
then infected the cells with CCHFV. We found that cells transfected
with the Rab5 WT or a pEGFP-C1 control also showed evidence
of CCHFV infection, as measured by the presence of CCHFV N.
In contrast, the majority of Rab5 DN transfected cells were not
infected with CCHFV (Fig. 5A). CCHFV infection was decreased
signiﬁcantly in the Rab5 DN transfected cells when compared
to the Rab5 WT (po0.0001) (Fig. 5B). Conversely, the Rab5
WT construct increased CCHFV infection when compared to the
pEGFP-C1 control (Fig. 5B). This increase in infection with Rab5
WT was shown previously with EE-dependent viruses such as VSV
(Pasqual et al., 2011). We used EBOV as a Rab5-dependent control
Fig. 4. Threshold of pH inactivation. (A) CCHFV, NiV-PsV, and VSV-GFP were pre-treated with buffers of various pH as indicated and then were neutralized to a pH of 7.2–7.4
as described in Materials and Methods. 293T cells were then infected with each pre-treated virus in replicates of 6. The data shown is representative of three experiments.
(A) Infectivity was assessed using the HCI described in the Materials and Methods, and data acquired from greater than 20,000 cells were analyzed per experimental point
and normalized to the pH 7.0 treated virus. (B) 20 magniﬁcation images from the high-content imaging system demonstrates that treatments did not affect cell viability.
CCHFV N is shown in green, with the nuclei stained with Hoechst 33342 shown in (blue).
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speciﬁc Rab7 GTPase for entry (Saeed et al., 2010). We found that
EBOV infection was decreased signiﬁcantly when comparing
the Rab5 DN with the Rab5 WT (po0.0001) (Fig. 5B). The data
indicate that CCHFV requires passage at least through EE for
cell entry.
We performed a similar experiment using a dominant-negative
version of the LE-speciﬁc Rab7 GTPase to determine if CCHFV also
trafﬁcs through the LE compartment. Cells were transfected with
Rab7 WT fused to Ds-Red, Rab7 T22N (DN) fused to DsRed, or
DsRed-C1 control and subsequently infected with CCHFV (Fig. 6A).
Whereas EBOV-GFP infection was decreased in Rab7 DN expres-
sing cells in comparison to the pDsRed-C1 control and to Rab7 WT
(p¼0.0001) (Fig. 6B), CCHFV infection rates were similar in all
transfected cells. The data indicate that CCHFV does not require LE
trafﬁcking for entry.Conclusion
Identifying speciﬁc entry requirements for viruses has led to
the development of antivirals that block infection. For example,
therapeutic fusion inhibitors have been developed for HIV-1 and
dengue viruses (Costin et al., 2010; Kilby et al., 1998; Nicholson
et al., 2011; Poh et al., 2009) and the anti-malarial drug chlor-
oquine, is being investigated as a treatment for the alphavirus
Chikungunya virus as it presumably prevents entry of the virus
through inhibiting endosomal acidiﬁcation (Khan et al., 2010). Our
work with CCHFV provides similar potential targets for therapeutic
intervention, in that we present convincing evidence that CCHFV
enters cells through the CME pathway and that the virus has an
acid-dependent fusion requirement. The data are consistent with
earlier ﬁndings, but are more convincing in that we used methods
that selectively inhibit CME without interfering with other host
cell processes. We also provide novel information suggesting that
AP2 is a cargo adapter for CCHFV CME. Further, we show for
the ﬁrst time that CCHFV is an early-penetrating member of
the family Bunyaviridae, along with LACV and possibly RVFV,
which utilize the EE for fusion. Future work, to include deﬁningthe speciﬁc conformational changes in the viral fusion protein that
are triggered in the EE, which permit membrane mixing, should
suggest additional potential targets and lead to the development
of treatments for infections caused by this rare but deadly virus.Materials and methods
Cells, viruses, and pseudovirions
A549 cells (ATCC# CCL-185) were maintained in F12-K medium
(Gibco) supplemented with 10% (v/v) fetal bovine serum
(FBS) (ThermoScientiﬁc/Hyclone, Logan, UT). HEK 293T (ATCC#
HB-8065), HepG2 (ATCC# CRL-11268), and CER (USAMRIID, Fort
Detrick, Frederick, MD) cells were maintained in Eagle's minimal
essential medium (EMEM) (Invitrogen, Carlsbad, CA) supplemen-
ted with 10% (v/v) FBS. All cell lines were maintained at 37 1C and
5% CO2 during incubations. Cells were plated on poly-D-lysine-
coated black 96-well clear bottom plates (Greiner Bio One,
Monroe, NC) for all experiments. The viruses used in this study
include: CCHFV strain IbAr 10200 (USAMRIID collection); vesicular
stomatitis Indiana virus expressing enhanced green ﬂuorescent
protein (VSV-eGFP), which was a generous gift from John Connor
(Boston University); vaccinia virus Western Reserve-GFP (VACV-
eGFP), which was a generous gift from Arthur Goff (made at
USAMRIID, personal communication); Ebola virus (EBOV) (USAM-
RIID collection); and Ebola virus expressing eGFP (EBOV-eGFP)
(USAMRIID collection) (Towner et al., 2005). The CCHFV seed was
propagated in CER cells, whereas VSV-eGFP, EBOV, and EBOV-eGFP
were propagated in Vero cells in EMEM. All viruses, except for
VACV-eGFP, were collected from clariﬁed cell culture supernatants.
VACV-eGFP was harvested from cell culture supernatant and cell
lysates. CCHFV, EBOV, and EBOV-eGFP were handled in biosafety
level 4 containment at USAMRIID. The Nipah virus lentivirus-based
pseudovirus (NiV-PsV) expressing red ﬂuorescent protein (RFP) was
a generous gift from Robert Doms (University of Pennsylvania)
(Khetawat and Broder, 2010). The VSV-based Ebola Zaire'76 pseu-
dovirus (EBOV-Z76 PsV) expressing luciferase protein was made at
USAMRIID as previously described (Higa et al., 2012).
Fig. 5. CCHFV cell entry is dependent on Rab 5. 293T cells were transiently transfected with Rab5-GFP S34N, Rab5-GFP wild type, or a pEGFP-C1 in replicates of six and then
infected with CCHFV or EBOV 24 h later. (A) 20 magniﬁcation images from the high-content imaging system, CCHFV N is shown in red, Rab5 WT and DN in green, with the
nuclei stained with Hoechst 33342 shown in blue. (B) Relative infection rates were determined by an Opera confocal reader with more than 19,000 cells analyzed per
experimental point. Conﬁdence interval was set to 95%.
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For all high-content imaging (HCI) experiments, CCHFV N was
detected using the mouse monoclonal antibody 9D5 (Altamura
et al., 2007). EBOV GP was detected using a mouse monoclonal
antibody 6D8 (Wilson et al., 2000). The cells were permeabilized
using 0.1% Triton-x 100 (Sigma-Aldrich) for 5 min at room tem-
perature, then the cells washed twice in PBS. For the EBOV-Z76 PsV
the cells were permeabilized using cold 50:50 solution of acetone
(Sigma-Aldrich) and methanol (Sigma-Aldrich) for 10 min at −70 1C.
A blocking solution containing 3% bovine serum albumin in PBS
(Sigma-Aldrich) was added to the cells, and they were incubated at
room temperature for 30–60 min to block non-speciﬁc epitopes.
The primary antibodies for CCHFV N and EBOV GP were diluted to
1 ng/ml, and 100 ml was added to each plate and incubated for 1 h.
The primary antibody, rabbit polyclonal anti-renilla luciferase anti-
body (MBL International Corporation), was used at a 1:400 dilution
to detect the luciferase protein from the EBOV-Z76 PsV. The cells
were thenwashed four times in PBS. For CCHFV N protein and EBOV
GP protein detection in all experiments, either an AlexaFluor 488-
or AlexaFluor 568-conjugated goat anti-mouse secondary antibody
(Invitrogen) was used, and an AlexaFluor 568 conjugated goat anti-
rabbit antibody (Invitrogen) was used for the EBOV-Z76 PsV
detection. The secondary antibody was added to each well at aconcentration of 2 ng/ml and the plates were incubated at room
temperature for 1 h, then the cells were washed three times in PBS.
The cell nuclei were stained with 1 mg/ml of Hoechst 33342 stain
(Invitrogen), and the plasmamembranes were stained with 500 ng/ml
of CellMask Deep Red (Invitrogen).
High-content data were acquired and analyzed on either an
Operetta (PerkinElmer, Waltham, MA, USA) high-throughput, wide-
ﬁeld ﬂuorescence microscope reader (PerkinElmer, Waltham, MA
02451) using the non-confocal setting with a 20 objective, or on
the Opera confocal reader (model 5025-Quadruple Excitation High
Sensitivity (QEHS), PerkinElmer) with a 10 air objective. On the
Operetta images in the Blue (Hoechst 33342), Green (GFP or
Alexa488), Red (Cherry/RFP or Alexa568) and Far Red (Cell Mask
Deep Red) channels were sequentially acquired by a single charged
coupled device (CCD) camera. For each ﬁeld of acquisition, a single
imaging plane was automatically set by using an infrared laser
based autofocus unit. The excitation light was provided by a 300 W
Xenon lamp and images were acquired using a 20 long working
distance objective. The settings for the excitation (EX)/emission
(EM) ﬁlters used for the different channels were as follows: Blue EX
360-400, EM 410-480; Green EX 460-490 EM 590-640; Red DM EX
560-580, EM 590-640; Far Red EX 620-640, EM 650-700. Image
analysis was performed on the ﬂy by using the Harmony 3.0 soft-
ware package (PerkinElemer). On the Opera confocal reader, the
Fig. 6. CCHFV is not dependent on Rab 7. 293T cells were transiently transfected with Rab7-DsRed T22N, Rab7-DsRed wild type, or a pDsRed in replicates of six and infected
with CCHFV or EBOV-eGFP 24 h later. (A) 10 magniﬁcation images from the high-content imaging system, CCHFV N is shown in green, Rab7 WT and DN in red, with the
nuclei stained with Hoechst 33342 stain (blue). (B) Relative infection rates were determined by an Opera confocal reader with more than 50,000 cells analyzed per
experimental point. Conﬁdence interval was set to 95%.
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to excite the viral and cell body ﬂuorophores, respectively. The
emission light was split by a 580 nm short pass dichroic mirror and
collected on separate cameras through 562/40 nm and 690/70 nm
band pass ﬁlters. The second exposure used a 425 nm long pass to
steer the UV (350 nm) to the sample to excite the nuclear stain. The
visible emission was directed to the non-confocal camera by a
475 nm long pass ﬁlter with the emission deﬁned with a 450/50 nm
band pass ﬁlter. High-content quantitative imaging data were
acquired and analyzed on an Opera confocal reader (model 3842-
Quadruple Excitation High Sensitivity (QEHS), PerkinElmer), at two
exposures using a 10 air objective. Analysis of the images was
accomplished within the Opera environment using standard Aca-
pella scripts.
HCI assay development and statistics
We developed and optimized speciﬁc and reproducible auto-
mated high-content image-based (HCI) assays for each virus used
throughout this study to evaluate the effects of different treat-
ments on virus replication. For each virus, we took care to
optimize the cell density and virus MOI for each HCI assay. The
statistics were performed in Excel as described previously to
determine the robustness of each assay (Zhang et al., 1999). To
determine the quality of the assay, statistical equations for signal-to-noise ratio, percent coefﬁcient of variation (%CV) (which mea-
sures screening data variability), and Z′-values (which deﬁnes
the power of an assay to discriminate between a negative control
and a positive control) were applied (Ljosa and Carpenter, 2009;
Panchal et al., 2010; Shariff et al., 2010). The % coefﬁcient of
variance (%CV) was calculated to determine the reproducibility
between replicates within a plate as follows:
ðmeanCstandard deviation of the meanÞ  100:
A %CV of less than 5% was considered optimal, and a higher %CV
was acceptable provided the Z′-value was within the acceptable
range as described below. The Z′-values were calculated for the
development of each assay to assess the assay quality using the
standard deviation of the infected wells (sc+) and the standard
deviation of the negative (mock) controls (sc−) using the following
equation:
Z′¼ 1− ð3scþ þ 3sc−Þðμcþ−μc−Þ
:
Z′-values between 0.5 and 1.0 were indicative of a high-quality
assay. A conﬁdence interval of 95% was used for all student t tests,
and a p-value of 0.05 or below was considered statistically
signiﬁcant.
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A549 cells were treated at 37 1C with Pitstop 2 (Abcam) at
concentrations ranging from 3.75 mM to 25 mM in a maximum of
0.1% DMSO. DMSO concentration matched control and media-
alone controls were also used for each virus. The drug or controls
were added to cells in triplicate for 15 min at 37 1C. The cells
were then infected with CCHFV, VACV-eGFP, or VSV-eGFP in the
presence of the drug at 37 1C for 1 h. Unbound virus was washed
away with PBS (Cellgro, Manassas, VA), and the cells were
incubated for an additional 6 h for VSV-eGFP, or 24 h for CCHFV
and VACV-eGFP in the presence of the drug. Infected cells were
ﬁxed in 10% buffered formalin for 24 h before staining. CCHFV N
protein was detected as described above. The plates were read and
analyzed on the Operetta reader, and normalized to the DMSO
matched control. At least 6000 cells were scored per experimental
point for each virus to determine the percent of infection. The cell
viability was determined by comparing the overall cell number per
experimental point to the DMSO matched controls. All concentra-
tions of DMSO showed no toxicity when compared to media alone.
siRNA-mediated knockdown
For the inhibition of proteins involved in CME, siRNAs were
used to inhibit the expression of subunits of AP2. A549 cells were
reverse-transfected in 96-well plates (20,000 cells per well) with
40 nM of siRNA targeting AP2A1 (ON-TARGET Plus), AP2A2 (ON-
TARGET Plus), AP2M1 (ON-TARGET Plus), or Non-Targeting Control
(Thermo Scientiﬁc/Dharmacon, Lafayette, CO) or in the absence
of siRNA using HiPerfect (Qiagen). In each well of a poly-D-lysine
coated 96-well clear-bottom plate, 40 nM of each siRNA was
diluted in triplicate in Optimem (Gibco/Invitrogen) to a ﬁnal
volume of 25 ml. A master mix of and 0.75 ml of HiPerfect and
24.25 ml of Optimem per well was prepared and added to each
well containing siRNA, or control wells, and mixed well by
pipetting. Then 20,000 A549 cells were added to each well, and
the siRNA and cells were mixed well by rocking the plate.
Cells were infected 48 h posttransfection, and replicate plates
were used for cellular mRNA extraction and qRT-PCR analysis.
Total cellular RNA was extracted from the siRNA transfected A549
cells using an RNeasy extraction kit (Qiagen, Valencia, CA) per the
manufacturer's instructions. Total mRNA from each sample was
diluted to 5 ng/ml, and 25 ng of each total mRNA was used in each
qRT-PCR reaction, in triplicate. Gene target mRNA was detected
using AP2A1 and AP2M1 primer/probe20 reaction sets (Applied
Biosystems, Carlsbad, CA) and TaqMans Reverse Transcription
reagents (Applied Biosystems), and normalized to a housekeeping
gene control, PPIB. The samples were run and analyzed on the
7900HT Fast Real-Time PCR System (Applied Biosystems) using
the following cycling proﬁle: 1 cycle at 50 1C for 30 min, 1 cycle at
95 1C for 10 min, followed by 40 cycles at 95 1C for 15 min and
60 1C for 30 min. The ΔΔCT was calculated for each sample and
normalized to the peptidylprolyl isomerase B (PPIB) housekeeping
control for each sample. The percentage of mRNA knockdown for
each siRNA target was calculated in comparison to the non-
targeting siRNA control.
To conﬁrm the ﬁndings from the single knockdownwe performed
a double knockdown experiment with the AP2M1 speciﬁc siRNA and
included a positive control, EBOV-Z76 PsV. A549 cells were reverse-
transfected in a 24-well plate (111,000 cells per well) with 80 nM
siRNA targeting AP2M1 (ON-TARGET Plus), or Non-Targeting Control
(Thermo Scientiﬁc/Dharmacon, Lafayette, CO) or in the absence
of siRNA using HiPerfect (Qiagen) and re-transfected 48 h later. In
a 24-well plate 80 nM of each siRNA was diluted in triplicate in
Optimem (Gibco/Invitrogen) a master mix of HiPerfect and Optimem
per well was prepared per the manufacturer's instructions and addedto each well containing the siRNA, or control wells, and mixed well by
pipetting. Then 110,000 A549 cells were added to each well, and the
siRNA and cells were mixed well by rocking the plate. Cells were re-
transfected 48 h later, and 24 h after the second transfection they
were re-seeded into black 96-well clear-bottom plates (20,000 cells
per well). The cells were infected 24 h after they were re-seeded, and
replicate plates were used for western blot analysis.
AP2 knockdown was veriﬁed by western blotting. Brieﬂy, three
wells of each of the transfected cell samples were lysed in a total
of 100 ml of Triton-X 100 lysis buffer: 1% Triton-X 100 (Sigma),
150 mM sodium chloride (Sigma), 5 mM ethylenediaminetetraa-
cetic acid (Sigma), 50 mM tris-hydrochloride (Sigma). LDS-page
buffer (Life Technologies) and sample reducing agent (Life Tech-
nologies) were added to each sample and the mixture was
incubated at 70 1C for 10 min. The samples were then loaded onto
a 4–12% Bis–Tris gel (Life Technologies) at 200 V for 50 min. The
proteins were transferred to a 0.45 PVDF membrane (Invitrogen).
The following primary antibodies were used to detect the AP2
proteins: a rabbit AP2M1 monoclonal antibody (Lifespan Bios-
ciences) was used at a 1:1000 dilution, and a mouse α-Adaptin
2 monoclonal antibody (F-12) (Santa Cruz Biotechnology, Inc)
was used at a 1:100 dilution. As a loading control glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was detected using a mouse
GAPDH monoclonal antibody (G-9) (Santa Cruz Biotechnology, Inc)
at a 1:1000 dilution. The mouse antibodies were detected using a
horse radish peroxidase (HRP) conjugated goat anti-mouse IgG
Fc secondary antibody (Abcam), the rabbit antibody was detected
using an HRP-conjugated goat anti-rabbit IgG H&L antibody
(Abcam). The HRP signal was developed with SuperSignal west
femto chemiluminescent substrate (Thermo Scientiﬁc).
Lysomotrophic drug assay
293T cells were pre-treated with ammonium chloride at con-
centrations of 1–25 mM, or media alone for 60 min before infection
with VSV-GFP, CCHFV, or EBOV-GFP for 16, 24, and 48 h, respec-
tively. The infected cells were then ﬁxed in 10% buffered formalin for
24 to 72 h before staining. CCHFV N protein was detected using the
N-speciﬁc mouse monoclonal antibody 9D5, and an AlexaFluor 488-
conjugated goat anti-mouse secondary antibody as described above.
The nuclei and cytoplasm were also stained as described above, and
the plates were read and analyzed on the Operetta reader. The
percent of infection was determined in each experimental point and
normalized to the mock control for each virus.
pH sensitivity assay
Low pH buffers ranging from pH 4.5 to pH 7.0 were prepared
from EMEM (Cellgro) without FBS, 200 mM 2-(N-morpholino)
ethanesulfonic acid (Sigma-Aldrich) was added, and the pH was
adjusted with sodium hydroxide or hydrochloric acid. CCHFV, NiV
pseudotype, and VSV were pre-treated with the low pH buffers for
15 min at 37 1C before neutralization to a pH of 7.2–7.4. Neutraliz-
ing buffers were made from EMEM with 100 mM Trizma pH 8.0
(Sigma-Aldrich), and pH adjusted with sodium hydroxide. After
the virus dilutions were neutralized, 293T cells were infected with
the neutralized virus samples for 2 h in replicates of six. Unbound
virus was then washed away with PBS and replaced with EMEM
with 10% FBS. The infections continued for 7 h for VSV-GFP, 16 h
for NiV-RFP pseudovirus, and 24 h for CCHFV. CCHFV N protein
was detected utilizing 9D5 antibody and an AlexaFluor-488 goat
anti-mouse secondary antibody as described above. The nuclei of
the cells and the cytoplasm were stained as described above and
the plates were read and analyzed on the Operetta reader. The
percent of infection in greater than 20,000 cells was determined
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virus data.
Dominant negative blockage of CCHFV entry and fusion
Transfections of plasmids expressing genes encoding wild-type
(WT) and dominant negative (DN) Rab proteins were performed in
293T cells to determine their effects on CCHFV entry. Rab5 WT and
DN tagged with GFP in pEGFP-C1 and were kindly provided by
Robert Davey (Texas Biomedical Research Institute). Rab7 WT and
DN tagged with DsRed in pDsRed-C1 (Clontech, Mountain View, CA)
and were kindly provided by Richard E. Pagano (Choudhury et al.,
2002). Negative controls used in all experiments included pEGFP-C1
(Clontech) or pDsRed-C1 (Clontech), and pcDNA3.1 (Invitrogen).
293T cells were plated at a density of 1104 cells per well in a
96-well poly-D-lysine coated black clear-bottom plate 24 h before
transfection. Each plasmid was transfected at a concentration of
0.05 mg per well using Fugene HD (Promega, Madison, WI) accord-
ing to the manufacturer's protocol for 293T cells. Fugene HD was
added at a 3:1 ratio of Fugene HD to DNA, and incubated for 5 min
before adding the mixture to the cells. 24 h posttransfection, the
cells were infected with CCHFV, EBOV, or EBOV-eGFP as a control.
For the infection the medium was removed from the cells and the
diluted virus was added in a volume of 50 ml per well at an
multiplicity of infection (MOI) of 2 for CCHFV, and an MOI of
2.5 for EBOV or EBOV-eGFP. The plates were incubated with virus at
37 1C for 1 h, then the inocula were removed and 100 ml of fresh
medium was added. CCHFV plates were ﬁxed in 10% buffered
formalin 24 h postinfection, EBOV plates were ﬁxed at 48 h post-
infection. The cells were ﬁxed in 10% formalin for 24 to 72 h before
bringing them out of the BSL-4 laboratory. Immunoﬂuorescence was
then carried out to detect CCHFV N and EBOV GP using monoclonal
antibodies 9D5 and 6D8 respectively. An AlexaFluor 568-conjugated
goat anti-mouse secondary (Invitrogen) was then used to detect the
monoclonal antibodies for GFP transfected cells, or AlexaFluor 488-
conjugated goat anti-mouse (Invitrogen) for DsRed-expressing cells.
The nuclei of the cells and the cytoplasm were stained as described
above and the plates were read and analyzed on the Operetta or
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